Novavax | NVAX - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Adma Biologics USD 1.63M 54K 2025-12
Agenus USD 16.02M 2.85M 2025-12
AstraZeneca USD 484M 181M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Cassava Sciences USD 129.73M 5.65M 2025-09
Geron USD 7.3M 1.35M 2025-12
GlaxoSmithKline GBP 167M 21M 2026-03
MannKind USD 13.87M 6.54M 2025-12
Merck USD 479M 67M 2026-03
Minerva Neurosciences USD 2.31M 60K 2024-06
Moderna USD 11.49B 36B 2026-03
Novartis USD 281M 8M 2025-09
Novavax USD 5.82M 342K 2025-12
Pfizer USD 711M 59M 2025-12
Sanofi EUR 178M 203M 2026-03
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
TG Therapeutics USD 6.53M 187K 2025-12